Gemcitabine

Where the papers sit

32 papers from the last 6 months study gemcitabine directly · updated from PubMed 10 Oct 2026

• Cancer Immunity and Drug Resistance

  Immune activation, treatment resistance and targeted delivery recur across breast cancer, lymphoma and central nervous system studies. Checkpoint blockade, CD40 agonism and chemotherapy are being combined to expand effector CD8+ T-cell responses or improve tumor inflammation. Breast cancer work links chromatin and DNA-repair programs to resistance and tests immune-responsive nanomedicine. Intraventricular gemcitabine addresses the blood-brain barrier, while glofitamab combinations extend therapy in relapsed DLBCL; no single clinical direction unifies the set.

  10 papers · 31.2%

• Pancreatic Cancer Treatment

  Pancreatic ductal adenocarcinoma treatment is moving toward biomarker-guided combinations that address metabolism, stroma and drug delivery. Gemcitabine is paired with S-1 or nab-paclitaxel, while co-targeting oxidative phosphorylation and pyrimidine synthesis seeks to restore response. Nanoparticles, organoid xenografts and stromal-remodeling studies are refining combination design and tumor-microenvironment analysis. Artificial-intelligence biomarkers and nutritional risk measures aim to select patients most likely to benefit and sustain therapy.

  9 papers · 28.1%

• gemcitabine Combination Therapy

  Gemcitabine-based treatment is being examined across biliary, urothelial and rare renal cancers, alongside a mechanistic study of gallbladder resistance. In gallbladder cancer, SUMOylated Reptin activates mitophagy, lowers ROS and supports cisplatin-gemcitabine resistance. Clinical work tests gemcitabine with nab-paclitaxel, cisplatin or doxorubicin, while enfortumab vedotin plus pembrolizumab provides a comparator in urothelial carcinoma. Response prediction and antiemetic support remain practical aims rather than a unified therapeutic direction.

  6 papers · 18.8%

• Cholangiocarcinoma Signaling and Resistance

  Intrahepatic cholangiocarcinoma research is shifting toward combination therapy and molecular explanations of gemcitabine response. Andrographolide plus gemcitabine targets RRM2 and JAK signaling, while fibroblast-associated TPM2 links matrix remodeling, EMT and Notch signaling to resistance. DOT1L expression is being evaluated as a biomarker for gemcitabine benefit. Trans-arterial versus intravenous delivery adds a pharmacokinetic question, but the central focus remains tumor signaling and treatment sensitivity.

  4 papers · 12.5%

• gemcitabine Resistance and Tumor Immunity

  gemcitabine resistance is being addressed through metabolic inhibition, immune modulation and drug-delivery design across several cancer types. Glycolytic inhibition and redox-responsive gemcitabine-quinine assemblies aim to overcome multidrug resistance. In colorectal cancer, gemcitabine-induced lactylation may increase sensitivity to anti-PD-L1 therapy. The shared direction is toward combination treatment, although the mechanisms and disease settings remain heterogeneous.

  3 papers · 9.4%